| PARRA, HECTOR SOTO |
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy |
|
|
| Active, not recruiting | 3 | 151 | Europe, US, RoW | Pyrotinib, Irene, Docetaxel, Docetaxel injection | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous NSCLC, HER2 Exon 20 Mutation | 06/23 | 10/23 | | |
| Recruiting | 3 | 162 | Europe | Atezolizumab 1200 mg in 20 ML Injection, Placebo | Gruppo Oncologico Italiano di Ricerca Clinica, Roche S.p.A. | Mesotheliomas Pleural | 12/23 | 12/23 | | |
SUNRAY-01, NCT06119581: A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) |
|
|
| Recruiting | 3 | 756 | Europe, US, RoW | Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Limited-stage Small Cell Lung Cancer (LS-SCLC) | 07/27 | 07/29 | | |
| Recruiting | N/A | 3000 | Europe | | Federation of Italian Cooperative Oncology Groups, Roche Pharma AG, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, LP, Takeda, Amgen, Daiichi Sankyo, Inc., Eli Lilly and Company, Novartis, Clinical Research Technology S.r.l. | Solid Tumours in Advanced Stages | 10/26 | 10/26 | | |
| Morabito, Alessandro |
SUNRAY-01, NCT06119581: A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-Small Cell Lung Cancer Who Have Progressed on Prior Anti- Programmed Death-ligand 1 (PD-[L]1) Therapy and Chemotherapy |
|
|
| Active, not recruiting | 2/3 | 758 | Europe, Canada, Japan, US, RoW | Cobolimab, Dostarlimab, Docetaxel | GlaxoSmithKline | Lung Cancer, Non-Small Cell | 10/24 | 10/25 | | |
| Active, not recruiting | 2 | 108 | Europe | paclitaxel, carboplatin, cetuximab | National Cancer Institute, Naples | Cervical Cancer | 12/24 | 12/24 | | |
|
| Not yet recruiting | 2 | 206 | Europe | Atezolizumab, Bevacizumab | Fondazione Ricerca Traslazionale | Non-small-cell Lung Cancer Patients | 05/22 | 04/23 | | |
MP-LALC, NCT03379441: Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLC |
|
|
| Not yet recruiting | 2 | 126 | Europe | Pembrolizumab Injectable Product | University of Turin, Italy | Non Small Cell Lung Cancer Patients | 01/23 | 01/23 | | |
MILES-5, NCT03975114: A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC |
|
|
| Recruiting | 2 | 460 | Europe | Chemotherapy, Durvalumab, Tremelimumab | National Cancer Institute, Naples, University of Campania "Luigi Vanvitelli", AstraZeneca | Carcinoma, Non-Small-Cell Lung | 12/23 | 06/24 | | |
| Recruiting | 2 | 170 | Europe | Osimertinib, Tagrisso, Dacomitinib, Vizimpro | Fondazione Ricerca Traslazionale, Pfizer srl | NSCLC | 12/23 | 12/23 | | |
| Active, not recruiting | 2 | 16 | Europe | ziconotide | National Cancer Institute, Naples | Pain, Neuropathic Pain, Intractable Pain, Cancer | 12/24 | 12/24 | | |
THOR, NCT05623319: Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) |
|
|
| Recruiting | 2 | 60 | Europe | Pembrolizumab/Olaparib | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Merck Sharp & Dohme LLC | SCLC,Extensive Stage | 08/26 | 08/26 | | |
NCT04416672: Validation of the Italian Version of the PRO-CTCAE |
|
|
| Recruiting | N/A | 3675 | Europe | PRO-CTCAE items | National Cancer Institute, Naples | Malignant Neoplasms | 07/24 | 07/24 | | |
| Active, not recruiting | N/A | 400 | Europe | | National Cancer Institute, Naples | Ovarian Cancer | 11/24 | 11/24 | | |
I-STOP, NCT05418660: Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC |
|
|
| Recruiting | N/A | 300 | Europe | Immunotherapy, Nivolumab, Pembrolizumab, Atezolizumab | University of Milano Bicocca, Azienda Ospedaliera San Gerardo di Monza | Non-small Cell Lung Cancer | 11/24 | 11/24 | | |
PETRA, NCT02035683: PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy |
|
|
| Active, not recruiting | N/A | 220 | Europe | PET/CT | National Cancer Institute, Naples | Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB | 12/24 | 12/24 | | |
| Bos, Reinhard |
BACH, NCT04985435: Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA |
|
|
| Recruiting | 4 | 100 | Europe | Filgotinib, Jyseleca, Anti-Tumor Necrosis Factor Alpha Drug (Product), Adalimumab (Humira) Etanercept (Enbrel), 50 patients will have a Free Choice between Filgotinib and anti TNF | R.Bos, Galapagos NV, Medical Centre Leeuwarden, Leiden University Medical Center | Rheumatoid Arthritis | 03/23 | 04/23 | | |
| Pilotto, Sara |
SUNRAY-01, NCT06119581: A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Not yet recruiting | 2 | 206 | Europe | Atezolizumab, Bevacizumab | Fondazione Ricerca Traslazionale | Non-small-cell Lung Cancer Patients | 05/22 | 04/23 | | |
| Recruiting | 2 | 33 | Europe | Alectinib | Gruppo Oncologico Italiano di Ricerca Clinica | Non Small Cell Lung Cancer | 05/23 | 05/26 | | |
LUNGVIR, NCT05597800: Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome |
|
|
| Not yet recruiting | 2 | 105 | Europe | Nivolumab and Ipilimumab, Opdivo and Yervoy | Universita di Verona | NSCLC Stage IV, HIV, HBV, HCV, Long COVID | 12/26 | 03/27 | | |
BOUNCE, NCT05718297: Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 44 | Europe | Brigatinib, Durvalumab | ETOP IBCSG Partners Foundation, Takeda | NSCLC, Stage III, ALK-rearrangement | 04/27 | 04/29 | | |
| Hamming, Lisanne |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Recruiting | 3 | 860 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 04/24 | 08/27 | | |
| Recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 10/24 | 06/27 | | |
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease |
|
|
| Active, not recruiting | 3 | 40 | Europe, Canada, Japan, US, RoW | Niraparib, Placebo | GlaxoSmithKline | Neoplasms, Breast | 03/25 | 08/29 | | |
|
| Vossenberg, T |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Overweight and Obesity | 02/29 | 02/29 | | |
